News & Updates

The probiotic strain Bifidobacterium breve (Bif195), when co-administered with aspirin, appears to mitigate stomach injury caused by aspirin, according to the results of a randomized crossover trial.

Tacrolimus appears to be more effective than cyclosporine in improving patient and graft survival after liver transplantation (LT) for primary sclerosing cholangitis (PSC), results of a study have shown.

The guanylate cyclase C agonist linaclotide helps increase the frequency of bowel movements in children with functional constipation, according to data from a phase III trial.

In advanced nonsmall cell lung cancer (NSCLC) patients with anorexia, treatment with mirtazapine leads to a substantial increase in energy intake despite having no effect on appetite, as shown in a study.

New drug applications approved by US FDA as of 01-15 January 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

In older patients with resected biliary tract cancer, adjuvant chemotherapy does not appear to yield significant survival gains when compared with observation, according to a study.

Treatment with rituximab (RTX) in children with juvenile dermatomyositis (JDM) and antibodies to antimelanoma differentiation-associated gene 5 (anti-MDA5) results in clinical improvements in interstitial lung disease (ILD) as well as in cutaneous manifestation and musculoskeletal disease activity, according to a study.

Treatment with ganaxolone in paediatric patients with cyclin-dependent kinase-like 5 deficiency disorder (CDD) leads to reductions in major motor seizure frequency (MMSF) over 2 years, according to data from the open-label extension phase of the Marigold trial.

Patients who received direct oral anticoagulants (DOACs) following transcatheter mitral valve replacement (TMVR) seem to have a lower risk of bleeding complications and shorter length of hospital stay, with no significant increase in the risk of thrombotic events, than those treated with vitamin K antagonists (VKAs), a study has shown.